<?xml version='1.0' encoding='utf-8'?>
<document id="18221172"><sentence text="Structural development, haematological immunological and pharmacological effects of quinolones."><entity charOffset="84-94" id="DDI-PubMed.18221172.s1.e0" text="quinolones" /></sentence><sentence text="The interest of the medical community in quinolones has not decreased despite more than ten years of continuous and growing use of these agents"><entity charOffset="41-51" id="DDI-PubMed.18221172.s2.e0" text="quinolones" /></sentence><sentence text=" The constant need for new anti microbials has produced a variety of newer quinolones termed as I, II, III, and IV generation"><entity charOffset="75-85" id="DDI-PubMed.18221172.s3.e0" text="quinolones" /></sentence><sentence text=" Nalidixic acid and other early quinolones had limited use due to poor pharmacokinetics, relatively narrow antimicrobial spectrum of activity, and frequent adverse effects"><entity charOffset="1-15" id="DDI-PubMed.18221172.s4.e0" text="Nalidixic acid" /><entity charOffset="32-42" id="DDI-PubMed.18221172.s4.e1" text="quinolones" /><pair ddi="false" e1="DDI-PubMed.18221172.s4.e0" e2="DDI-PubMed.18221172.s4.e0" /><pair ddi="false" e1="DDI-PubMed.18221172.s4.e0" e2="DDI-PubMed.18221172.s4.e1" /></sentence><sentence text=" Extensive pharmacologic and clinical development of quinolone antimicrobial agents has resulted in improved antimicrobial activity, pharmacokinetic features, toxicity, and drug-drug interaction profiles"><entity charOffset="53-62" id="DDI-PubMed.18221172.s5.e0" text="quinolone" /></sentence><sentence text=" These attributes, coupled with their expanded spectrum and the immune enhancing phenomena of quinolones with a cyclopropyl moiety at position 1 of the quinolone ring suggest that the newer fluoroquinolones are so far the most ideal agents for the empirical treatment of many common infections"><entity charOffset="94-104" id="DDI-PubMed.18221172.s6.e0" text="quinolones" /><entity charOffset="112-123" id="DDI-PubMed.18221172.s6.e1" text="cyclopropyl" /><entity charOffset="152-161" id="DDI-PubMed.18221172.s6.e2" text="quinolone" /><pair ddi="false" e1="DDI-PubMed.18221172.s6.e0" e2="DDI-PubMed.18221172.s6.e0" /><pair ddi="false" e1="DDI-PubMed.18221172.s6.e0" e2="DDI-PubMed.18221172.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18221172.s6.e0" e2="DDI-PubMed.18221172.s6.e2" /><pair ddi="false" e1="DDI-PubMed.18221172.s6.e1" e2="DDI-PubMed.18221172.s6.e1" /><pair ddi="false" e1="DDI-PubMed.18221172.s6.e1" e2="DDI-PubMed.18221172.s6.e2" /></sentence><sentence text=" The above has made it desirable to review the status of these agents as revealed in published literature" /><sentence text=" The thrust of this review is on the structural development, pharmacological, haematological and immunological effects of quinolones"><entity charOffset="122-132" id="DDI-PubMed.18221172.s8.e0" text="quinolones" /></sentence><sentence text=" Recent patents filed are also discussed" /><sentence text="" /></document>